Product Description
ICP-B05 (CM369) is an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody, developed by a joint venture between InnoCare and Keymed called Tiannuojiancheng Pharma in China. There are no CCR8-targeted drugs approved for marketing in the world. ICP-B05 selectively depletes Tregs in the tumor microenvironment, which is more specific than other immunotherapies. A Phase I trial of ICP-B05 in the treatment of solid tumors is ongoing in China. (Sourced from: https://www.innocarepharma.com/en/development/pipeline)
Mechanisms of Action: CCR8 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innocare Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|